Abstract
Human epidermal keratinocytes (EKs) are metabolically involved in various drug transport mechanisms, as well as in detoxification or activation processes. The overall cell mechanisms of drug metabolization, and more specifically drug processing are reviewed in normal EKs. The overall drug metabolism involves different phases corresponding to the uptake, biotransformation and anti-transport steps. In EKs, both the enzymes and transportassociated proteins are different from those involved in the hepatocyte metabolism. Some cytochrome P450 enzymes and the flavin-containing mono-oxygenases are particularly involved in EKs. Basically, EKs represent key cells likely involved during the initial stage of drug-induced toxic epidermal necrolysis (TEN). Only limited advances have been made so far in this field. Nevertheless, mitigating EKs metabolic disturbances in TEN probably represent a promising specific treatment of the disease.
Keywords: Drug metabolism, toxic epidermal necrolysis, drug disposition, biotransformation, anti-transport mechanism, cytochrome P450, keratinocyte, aromatic anti-epileptics, lamotrigine, pantoprazole
Current Drug Safety
Title:Drug Interactions with Normal and TEN Epidermal Keratinocytes
Volume: 7 Issue: 5
Author(s): Philippe Paquet, Philippe Delvenne and Gerald E. Pierard
Affiliation:
Keywords: Drug metabolism, toxic epidermal necrolysis, drug disposition, biotransformation, anti-transport mechanism, cytochrome P450, keratinocyte, aromatic anti-epileptics, lamotrigine, pantoprazole
Abstract: Human epidermal keratinocytes (EKs) are metabolically involved in various drug transport mechanisms, as well as in detoxification or activation processes. The overall cell mechanisms of drug metabolization, and more specifically drug processing are reviewed in normal EKs. The overall drug metabolism involves different phases corresponding to the uptake, biotransformation and anti-transport steps. In EKs, both the enzymes and transportassociated proteins are different from those involved in the hepatocyte metabolism. Some cytochrome P450 enzymes and the flavin-containing mono-oxygenases are particularly involved in EKs. Basically, EKs represent key cells likely involved during the initial stage of drug-induced toxic epidermal necrolysis (TEN). Only limited advances have been made so far in this field. Nevertheless, mitigating EKs metabolic disturbances in TEN probably represent a promising specific treatment of the disease.
Export Options
About this article
Cite this article as:
Paquet Philippe, Delvenne Philippe and E. Pierard Gerald, Drug Interactions with Normal and TEN Epidermal Keratinocytes, Current Drug Safety 2012; 7 (5) . https://dx.doi.org/10.2174/1574886311207050004
DOI https://dx.doi.org/10.2174/1574886311207050004 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Localization Patterns of Sumoylation Enzymes E1, E2 and E3 in Ocular Cell Lines Predict Their Functional Importance
Current Molecular Medicine Estrogen Receptor Ligands for Targeting Breast Tumours: A Brief Outlook on Radioiodination Strategies
Current Radiopharmaceuticals MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression
Current Cancer Therapy Reviews Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Lifelong and Prenatal Effects of Phytoestrogens
Current Bioactive Compounds Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets Reconsidering the Scenario of Cyberbullying: Promoting the Internalization of the Locus of Control in Adolescents through Cognitive Restructuring
Adolescent Psychiatry Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy
Current Molecular Pharmacology Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Imaging Methods in Gene Therapy of Cancer
Current Gene Therapy Zebrafish: Predictive Model for Targeted Cancer Therapeutics from Nature
Current Cancer Drug Targets Pyrrolo[2,1-c][1,4]benzodiazepine as a Scaffold for the Design and Synthesis of Anti- Tumour Drugs
Anti-Cancer Agents in Medicinal Chemistry Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets Glycomics: Relevance for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Mechanisms Controlling Sensitivity to Platinum Complexes: Role of p53 and DNA Mismatch Repair
Current Cancer Drug Targets Homocysteine and Cerebral Stroke in Developing Countries
Current Medicinal Chemistry Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer
Letters in Drug Design & Discovery